Amgen's Heart Drug Faces Higher Bar After Novartis Miss

Amgen's olpasiran has been given a tougher test as it aims to prove its worth in treating heart conditions. The biotech giant inherited this burden after Novartis's pelacarsen failed to cut major cardiovascular events, despite successfully lowering lipoprotein(a), or Lp(a). This outcome sends a warning signal across the entire Lp(a) drug class: reducing laboratory numbers may not directly translate to improved patient outcomes.

Amgen's OCEAN(a) outcomes study has enrolled 7,297 participants and will track coronary-heart-disease deaths, heart attacks, and urgent coronary procedures over five years. This trial uses a different drug design than pelacarsen, targeting a potentially different population. However, the failure of Novartis's drug strips away any easy assumptions investors may have made about the commercial value of reducing Lp(a) levels.

Amgen still holds significant financial muscle, backed by $10.1 billion in second-quarter revenue and $3.5 billion in free cash flow. However, with shares sitting 19.54% above their GF Value estimate of $365.76, the market will no longer reward olpasiran for simply reducing a biomarker. The drug must now prove it can prevent cardiovascular events that truly matter.